AZ-WALTON-GLOBAL-HLDNGS
Walton Global Holdings Ltd. and its affiliates (collectively Walton), a real estate investment and land asset company with US$3.8 billion under management and administration, has acquired the 245-acre Lee Farms property located at 4300 Wilson Ave. in Loveland, Colo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005268/en/
The pre-developed land is slated for a single-family residential master planned community of approximately 900 units, offering a variety of sizes and types of homesites. The parcel is located within close proximity to existing and actively selling new-home communities of Meadowbrook Ridge, Mariana Butte and The Lakes at Centerra.
The property was acquired from The True Life Companies and the Lee Family.
Located 14 minutes from Fort Collins, Colo., home to Colorado State University, the Loveland region boasts a strong economy featuring dozens of innovative businesses from tech start-ups to Fortune 500 companies, low unemployment, and a steady population growth that is driving demand for residential construction.
Brett Limbaugh, Director of Development Services for the City of Loveland believes this is a good time to take advantage of the current market conditions stating, “We are excited to work with Walton on moving the Lee Farms development forward and seeing additional growth in the market area.”
Concurrent to the purchase of the Lee Farms property, Walton has secured interest from a top publicly-traded homebuilder with plans to begin development of the land in 2020. Negotiations are underway with an Exit Focused Letter of Intent that affords the builder a first right of refusal for a phased procurement of the property. It is anticipated the land will be developed in multiple phases, providing distributions to investors as the builder sells homes.
The Loveland, Colo. land acquisition adds to Walton’s 85,000-acre portfolio located across the United States, providing a scalable land acquisition platform to support homebuilders with just-in-time inventory management. Walton’s approach is an innovative response to secular shifts in the land development industry, which is increasingly challenged to finance acquisition with debt.
Walton recently announced its first Builder Option Land Development fund (the BOLD Fund), that provides homebuilders with a land acquisition opportunity to work alongside an international real estate investment and asset management company for securing a land pipeline with minor upfront capital contribution.
“The benefits of working with national builders through these Exit Focused Agreements by holding land for future development, is opening up tremendous opportunities for Walton in all markets where we research and acquire land,” said Barry Dluzen, Senior Vice President - Land of Walton Global Holdings.
For over 40 years, Walton has researched, planned, and structured pre-development land investments located in the major growth corridors throughout the U.S. and Canada. The evolution of Walton has opened the door to offering new products, like the BOLD Fund, creating new opportunities for investors and homebuilders.
About Walton Global Holdings
Walton Global Holdings is a privately owned, leading global real estate investment, land asset management and administration company that has focused on strategically located land in major growth corridors for over 40 years. The company manages and administers US$3.8 billion of real estate assets in North America, on behalf of its investors and business partners. Walton has more than 106,000 acres of land under ownership, management and administration in the United States and Canada. For more information visit Walton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005268/en/
Contact:
MEDIA CONTACT: Jennifer Whittle LAVIDGE 480-998-2600 Jwhittle@lavidge.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
